Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.65 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.58 |
| ▸ | THRA | P10827 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.56 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9502541 | 1.00 | RARB (0.75) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL9274539 | 1.00 | RARB (0.75) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL7767495 | 1.00 | RARB (0.75) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL7766926 | 1.00 | RARB (0.75) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL7766930 | 1.00 | RARB (0.75) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL7768450 | 1.00 | RARB (0.75) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL9450551 | 0.98 | RARB (0.72) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL8728342 | 0.95 | TP53 (0.73) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL4209056 | 0.95 | TP53 (0.73) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL9161795 | 0.95 | TP53 (0.73) | RARBTP53TSHRPLA2G4BPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057173-B1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8119617-B2 | aSMase inhibitors | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| US-20100022482-A1 | aSMase inhibitors | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
| EP-2057173-A1 | AMIDES AS SPHINGOMYELINE INHIBITORS | Novartis AG (CH) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008022771-A1 | AMIDES AS SPHINGOMYELINE INHIBITORS | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | disclosed |
| EP-0630954-B1 | Low-molecular-weight and polymeric liquid cristalline benztriazoles and their use | BASF AG (DE) | 1997-01-08 | — | — | EP | disclosed |
| EP-0415833-B1 | Optically active fluorine-containing alcohol compounds and liquid crystal compounds therefrom | SHOWA SHELL SEKIYU (JP) | 1996-09-11 | — | — | EP | disclosed |
| EP-0381149-B1 | Optically active compound, liquid crystal composition and liquid crystal device comprising same | SHARP KK (JP) | 1996-03-27 | — | — | EP | disclosed |
| US-5429770-A | Photoconductors, electrography, fluorescent dyes | BASF AKTIENGESELLSCHAFT (DE) | 1995-07-04 | — | — | US | disclosed |
| EP-0422996-B1 | Liquid crystal compound | SHOWA SHELL SEKIYU (JP) | 1995-04-12 | — | — | EP | disclosed |
| EP-0409234-A2 | Alpha-hydroxyketone derivatives, liquid crystal compositions containing said derivatives, and liquid crystal devices using said compositions | Chisso Corporation (JP) | 1991-01-23 | — | — | EP | disclosed |
| EP-0259995-B1 | LIQUID CRYSTAL MATERIAL | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-10-17 | — | — | EP | disclosed |
| EP-0381149-A2 | Optically active compound, liquid crystal composition and liquid crystal device comprising same | SHARP KABUSHIKI KAISHA (JP) | 1990-08-08 | — | — | EP | disclosed |
| US-4906402-A | Liquid crystal material | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1990-03-06 | — | — | US | disclosed |
| EP-0315193-A2 | Optically active compound and chiral liquid crystal composition containing the same | NIPPON TELEGRAPH AND TELEPHONE CORPORATION (JP) | 1989-05-10 | — | — | EP | disclosed |
| EP-0297745-A1 | Optically active ether derivatives, preparation processes therefor, liquid crystal materials and an optical switching element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-01-04 | — | — | EP | disclosed |
| EP-0110299-B1 | SMECTIC LIQUID CRYSTAL COMPOUNDS AND LIQUID CRYSTAL COMPOSITIONS | HITACHI, LTD. (JP) | 1988-06-29 | — | — | EP | disclosed |
| EP-0259995-A1 | Liquid crystal material | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-16 | — | — | EP | disclosed |
| US-4576732-A | OPTICAL DISPLAYS | HITACHI, LTD. (JP) | 1986-03-18 | — | — | US | disclosed |
| EP-0110299-A2 | Smectic liquid crystal compounds and liquid crystal compositions | HITACHI, LTD. (JP) | 1984-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022482-A1 | aSMase inhibitors | SMPD1, SMPD3, SMPD2 | RARB 4739/4885TP53 4791/4885TSHR 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.